ET vs ARGX Comparison

Energy Transfer is a diversified midstream firm, operating from wellhead to consuming demand. It handles natural gas, natural gas liquids, or NGLs, crude oil, and refined products. Commodities are moved through its network of field level gathering and processing to refineries and demand centers. Operations are concentrated in Texas and the Midcontinent United States. It also controls Sunoco and USA Compression through its general partner relationship.

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.